iBio, Inc. (IBIO): who owns it and who trades it
As of Nov 16, 2026, IBIO insiders reported 4 purchases worth $98.1K in the last 12 months. The largest buyer was Felipe Duran (CFO), with $50.2K. 3 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling iBio
From the latest filingsOverall: more buying than selling. Famous investors mostly sold. Funds and insiders mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns IBIO
55 funds and institutions reported IBIO shares worth $60.8M at the end of Q2 2026, about 70% of the company. The largest holder is Affinity Asset Advisors, LLC with 8.1%.
Funds and institutions (13F) 70%Everyone else 30%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Affinity Asset Advisors, LLC | 4.01M | 8.07% | $7M | +29% |
| Cormorant Asset Management, LP | 3.57M | 7.19% | $6.2M | New |
| Silverarc Capital Management, LLC | 3.52M | 7.09% | $6.2M | +1458% |
| Vestal Point Capital, LP | 2.60M | 5.23% | $4.5M | New |
| Vanguard Capital Management LLC | 2.10M | 4.22% | $3.7M | +93% |
| Frazier Life Sciences Management, L.P. | 1.95M | 3.93% | $3.4M | No change |
| Ensign Peak Advisors, Inc | 1.83M | 3.69% | $3.2M | New |
| Woodline Partners LP | 1.78M | 3.58% | $3.1M | New |
| Millennium Management LLC | 1.65M | 3.32% | $2.9M | +7% |
| Citadel Advisors LLC | 1.38M | 2.79% | $2.4M | +45% |
| Balyasny Asset Management L.P. | 1.17M | 2.36% | $2M | +16% |
| Bank of America Corp | 1.12M | 2.26% | $2M | +286% |
| Ikarian Capital, LLC | 957,062 | 1.93% | $1.7M | No change |
| Sio Capital Management, LLC | 904,268 | 1.82% | $1.6M | No change |
| Marshall Wace, LLP | 904,132 | 1.82% | $1.6M | +46% |
| Geode Capital Management, LLC | 500,816 | 1.01% | $877K | +29% |
| Walleye Capital LLC | 500,375 | 1.01% | $876K | +29% |
| Squarepoint Ops LLC | 498,872 | 1.00% | $873K | New |
| Noesis Capital Mangement Corp | 405,000 | 0.82% | $709K | +30% |
| Two Sigma Investments, LP | 400,667 | 0.81% | $701K | -2% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, IBIO insiders reported $98.1K of open-market purchases and $0 of sales.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Mar 26, 2026 | Marc Banjak | Chief Legal Officer | Purchase | 12,500 | $1.64 | $20.5K | Form 4 |
| Mar 26, 2026 | Marc Banjak | Chief Legal Officer | Purchase | 1,434 | $1.76 | $2.5K | Form 4 |
| Mar 19, 2026 | Felipe Duran | CFO | Purchase | 24,835 | $2.02 | $50.2K | Form 4 |
| Mar 19, 2026 | Martin Brenner | Director | Purchase | 12,336 | $2.02 | $24.9K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Felipe Duran | Chief Financial Officer | $50.2K | – | Mar 19, 2026 |
| Martin Brenner | See Remarks, Director | $24.9K | – | Mar 19, 2026 |
| Marc Banjak | Chief Legal Officer | $23K | – | Mar 26, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
IBIO short interest
Moderate short interest. 6.3% of IBIO shares are sold short: about 1 share in 16. Over the last 12 reports the number of shares short went up 18%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 4.03M IBIO shares were sold short, 6.3% of the shares outstanding, up 8.0% from the report before. At the average daily volume of 563,738 shares, buying them all back would take about 7.2 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 4.03M | 6.27% | +8% | 563,738 | 7.2 |
| Oct 15, 2026 | 3.73M | 5.80% | -11% | 1.06M | 3.5 |
| Sep 30, 2026 | 4.20M | 6.53% | -15% | 681,565 | 6.2 |
| Sep 15, 2026 | 4.94M | 7.68% | -5% | 494,351 | 10.0 |
| Aug 31, 2026 | 5.20M | 8.09% | +4% | 895,038 | 5.8 |
| Aug 14, 2026 | 5.03M | 10.12% | -2% | 452,026 | 11.1 |
| Jul 31, 2026 | 5.11M | 10.28% | -5% | 732,757 | 7.0 |
| Jul 15, 2026 | 5.38M | 10.84% | +15% | 1.34M | 4.0 |
| Jun 30, 2026 | 4.69M | 9.45% | +25% | 924,957 | 5.1 |
| Jun 15, 2026 | 3.76M | 7.56% | -0% | 780,149 | 4.8 |
| May 29, 2026 | 3.76M | 7.57% | +10% | 781,885 | 4.8 |
| May 15, 2026 | 3.41M | 6.86% | -0% | 958,081 | 3.6 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
iBio company events
iBio filed 18 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Nov 10, 2026.
- Nov 10, 2026ResultsReleased financial results. Filing
- Oct 19, 2026LeadershipIBio, Inc. held its 2026 Annual Meeting of Stockholders. Filing
- Oct 13, 2026AnnouncementThe Company issued a press release highlighting preclinical body-composition data from its obese NHP study evaluating IBIO-610, potentially a first-in-class Activin E antibody candidate. Filing
- Sep 14, 2026AnnouncementThe Company has updated its corporate presentation for use in meetings with investors, analysts and others. Filing
- Aug 28, 2026ResultsReleased financial results. Filing
- Aug 4, 2026LeadershipMolly Carr, M.D. was appointed as the Chief Medical Officer of iBio, Inc. Filing
- Jul 17, 2026AnnouncementOf this Current Report on Form 8-K is incorporated by reference into this Item 5.08. Item 8.01. Filing
- Jul 1, 2026AnnouncementThe Company issued a press release announcing new preclinical data from its obese NHP study evaluating IBIO-610, potentially a first-in-class Activin E antibody candidate. Filing
- May 12, 2026ResultsReleased financial results. Filing
- May 8, 2026LeadershipThe Board of Directors of iBio, Inc., following the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Dr. Elizabeth Stoner, M.D., M.S., to serve as a Class II director of the Company, effective May 7, 2026, and to serve until the Company’s 2028 annual… Filing
- Apr 17, 2026AnnouncementAmended an earlier report. Of the Current Report on Form 8-K it filed with the Securities and Exchange Commission on April 8, 2026 to correct a typographical error contained therein regarding the date that the Series G warrants to purchase up to 35,770,000 shares of the Company’s common stock, par value $0.001 per share will… Filing
- Apr 8, 2026AnnouncementThe Company issued a press release announcing that it received Clinical Trial Notification acknowledgement from Australia’s Therapeutic Goods Administration and ethics approval from a Human Research Ethics Committee, enabling the initiation of a first-in-human clinical trial of IBIO-600 in… Filing
- Mar 9, 2026AnnouncementThe Company issued a press release announcing preclinical data from its obese NHP study evaluating IBIO-610, potentially a first-in-class Activin E antibody candidate. Filing
- Feb 27, 2026AgreementIBio, Inc., a Delaware corporation, entered into an Open Market Sale Agreement SM with Jefferies LLC providing for the sale by the Company of its shares of common stock, par value $0.001 per share, from time to time, through or to Jefferies in an at-the-market offering program as set forth in the… Filing
- Feb 10, 2026ResultsReleased financial results. Filing
- Jan 12, 2026AgreementIBio, Inc., a Delaware company, entered into a securities purchase agreement with certain institutional investors, pursuant to which the Company agreed to issue and sell to the Investors, in a private placement priced at-the-market consistent with the rules of the Nasdaq Stock Market LLC an… Filing
- Nov 21, 2025VoteReported shareholder vote results. Filing
- Nov 17, 2025AnnouncementThe Company has updated its corporate presentation for use in meetings with investors, analysts and others. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
iBio financials
Famous investors that hold IBIO
3 of the 50 well-known investors we track reported holding IBIO in their latest 13F filing. The largest position is Israel Englander's, worth $1.7M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Israel Englander · Millennium Management | Q3 2026 | 1.42M | $1.7M | 0.0% | -14% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 688,400 | $812K | 0.0% | +239% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 666,171 | $786K | 0.0% | -52% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named IBIO in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | Frazier Life Sciences Public Fund, L.P. | 13G/A | 3.0% |
| Nov 16, 2026 | Frazier Life Sciences Public Fund, L.P. | 13G/A | 3.0% |
| Oct 14, 2026 | Coastlands Capital LP | 13G | 9.7% |
| Oct 14, 2026 | Coastlands Capital LP | 13G | 9.7% |
Questions about iBio, Inc. (IBIO) stock
Who owns the most IBIO stock?
The largest reported owner of iBio, Inc. (IBIO) is Affinity Asset Advisors, LLC, with 8.1% of the company. In total, 55 funds and institutions reported holding IBIO at the end of Q2 2026, together about 70% of the shares. See the largest owners.
Are IBIO insiders buying or selling?
In the last 12 months, IBIO insiders reported 4 open-market purchases worth $98.1K and no sales. The latest trade was on Mar 26, 2026. See every trade.
What is the short interest in IBIO?
As of Oct 30, 2026, 4.03M IBIO shares were sold short, 6.3% of the shares outstanding, up 8.0% from the report before. At the average daily volume of 563,738 shares, buying them all back would take about 7.2 trading days (days to cover). See the history.
Which famous investors hold IBIO?
3 of the 50 well-known investors we track reported IBIO in their latest 13F filing, including Israel Englander, Jim Simons, Ken Griffin. The largest position is worth $1.7M. See all holders.
Executive pay
iBio's chief executive was paid a total of $2.1M for the year ended Jun 30, 2026, up 42% from $1.5M the year before. In the last 12 months, iBio's executives and directors bought $98.1K of stock on the open market and sold none.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.